Description

ASP5286 is a novel non-immunosuppressive cyclophilin inhibitor for the research of HCV.—COVID-19-anti-virus–C62H111N11O14—-[1]Makino T, et al. Discovery of ASP5286: A novel non-immunosuppressive cyclophilin inhibitor for the treatment of HCV. Bioorg Med Chem Lett. 2020 Aug 15;30(16):127308.–935735-70-9–1234.61—-O[C@@H]([C@](C(N[C@@](C(N([C@@H](C(N([C@@](C(N[C@H](C(N([C@H]1CC(C)C)C)=O)CC(C)C)=O)([H])[C@@H](C)OC)C)=O)C)C)=O)([H])[C@H](O)C)=O)([H])N(C([C@@H](N(C([C@@H](NC([C@@H](N(C([C@H](NC([C@@H](NC1=O)C)=O)C)=O)C)CC(C)C)=O)CC(C)C)=O)C)C(C)C)=O)C)[C@H](C)C/C=C/C–Infection–10 mM in DMSO–HCV—-Anti-infection–Peptides